Recursion Pharmaceuticals, Inc. (RXRX) quarterly cash flow statement — complete operating, investing & financing history
| Cash from Operations | -81.1M | -46.07M | -117.36M | -76.42M | -131.96M | -115.43M | -59.23M | -82.22M | -102.3M | -74.08M | -72.92M | -67.47M |
| Operating CF Margin % | -1253.11% | -129.64% | -2267.83% | -400.03% | -894.93% | -2558.86% | -227.07% | -570.81% | -758.28% | -697.26% | -721.84% | -612.45% |
| Operating CF Growth % | 38.54% | 60.09% | -98.16% | 7.06% | -28.99% | -55.82% | 18.78% | -21.87% | -39.53% | -65.54% | -33.7% | -9.48% |
| Net Income | -117.5M | -108.12M | -162.25M | -171.9M | -202.49M | -178.91M | -95.84M | -97.54M | -91.37M | -93M | -93.02M | -76.73M |
| Depreciation & Amortization | 19.67M | 19.48M | 21.04M | 23.85M | 19.33M | 12.95M | 7.2M | 8.97M | 7.38M | 7.55M | 7.58M | 5.54M |
| Stock-Based Compensation | 0 | 23.76M | 25.24M | 26.16M | 36.06M | 30.78M | 18.25M | 16.52M | 16.13M | 16.09M | 16.79M | 11.81M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 24.54M | 8.13M | 24.9M | 10.32M | 20.99M | 13.69M | 11.43M | -2.84M | 2.02M | 6.55M | 189K | 2.03M |
| Working Capital Changes | -7.8M | 10.68M | -26.3M | 35.15M | -5.85M | 6.05M | -264K | -7.33M | -36.45M | -11.27M | -4.46M | -10.12M |
| Change in Receivables | 14.75M | -836K | 3.53M | 25.41M | 4.84M | 0 | -939K | 736K | -1.04M | -6.42M | -203K | -814K |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Change in Payables | 2.07M | 4.42M | -5.89M | -4.84M | 3.69M | 8.12M | -1.51M | -1.34M | 1.17M | -317K | 2.19M | -2.52M |
| Cash from Investing | -338K | -1.24M | -2.55M | -5.81M | -7.27M | 275.46M | -4.56M | -4.18M | -6.65M | -2.49M | -347K | -2.05M |
| Capital Expenditures | -338K | -1.24M | -243K | -3.15M | -1.83M | -1.3M | -4.56M | -1.18M | -6.65M | -2.07M | -745K | -3.97M |
| CapEx % of Revenue | 5.22% | 3.5% | 4.7% | 16.49% | 12.42% | 28.77% | 17.49% | 8.21% | 49.31% | 19.46% | 7.37% | 36.02% |
| Acquisitions | 0 | 0 | 0 | 0 | -4.44M | 277.1M | 0 | 0 | 0 | -71K | 0 | 0 |
| Investments | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | -2.16M | 0 | -350K | 0 | -3M | 0 | -350K | -82K | 1.92M |
| Cash from Financing | -3.47M | 132.01M | 251.34M | 97.66M | 40.53M | 10.64M | 16.46M | 263.12M | 13.9M | 80.66M | 53.77M | 3.79M |
| Debt Issued (Net) | -2.21M | -2.17M | -2.13M | -2.08M | -2.05M | -2.1M | -2.29M | -26K | -26K | -694K | -24K | -24K |
| Equity Issued (Net) | 0 | 134.17M | 254.46M | 102.74M | 41.02M | 11.03M | 16.97M | 261.55M | 10.87M | 78.09M | 50M | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing | -1.26M | 0 | -993K | -3M | 1.55M | 1.71M | 1.78M | 1.6M | 3.05M | 3.26M | 3.79M | 3.81M |
| Net Change in Cash | -87.9M | 86.78M | 133.3M | 24.69M | -93.87M | 167.19M | -46.92M | 176.6M | -95.28M | 4.22M | -19.62M | -65.55M |
| Free Cash Flow | -81.36M | -47.32M | -117.6M | -79.57M | -133.79M | -117.08M | -63.79M | -86.4M | -108.95M | -76.49M | -73.75M | -71.44M |
| FCF Margin % | -1257.09% | -133.14% | -2272.52% | -416.52% | -907.35% | -2595.39% | -244.56% | -599.84% | -807.6% | -720.01% | -730.02% | -648.47% |
| FCF Growth % | 39.19% | 59.59% | -84.37% | 7.91% | -22.8% | -53.06% | 13.51% | -20.95% | -38.52% | -45.08% | -16.87% | 8.53% |
| FCF per Share | -0.15 | -0.09 | -0.26 | -0.19 | -0.33 | -0.35 | -0.23 | -0.36 | -0.46 | -0.33 | -0.34 | -0.35 |
| FCF Conversion (FCF/Net Income) | 0.69x | 0.43x | 0.72x | 0.44x | 0.65x | 0.65x | 0.62x | 0.84x | 1.12x | 0.80x | 0.78x | 0.88x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 60K | 11K | 12K |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |